Navigation Links
National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
Date:12/1/2011

Hackensack, N.J. (December 1, 2011) - The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

More than half of the John Theurer Cancer Center presentations showcased at the ASH Annual Meeting have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, multi-center, international trials in collaboration with leading cancer institutions such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, and Memorial Sloan-Kettering.

"Personalizing therapies will certainly play a growing role in the practice of oncology," said Andre Goy, M.D., M.S., chairman and director, chief of lymphoma, and director, clinical and translational cancer research. "Our center is part of many studies researching novel therapies as well as the identification of biomarkers predictive of outcomes in cancer."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia.

Seven John Theurer Cancer Center physicians are first or senior authors, including Dr. Goy; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Anthony Mato, M.D., oncologist, lymphoma; Joshua Richter, M.D., oncologist, multiple myeloma; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma; and David Vesole, M.D., Ph.D., co-chief and director of research, multiple myeloma.

John Theurer Cancer Center experts will also participate in panel discussions and moderate sessions. Dr. Siegel will present a complicated case at the International Hematologic Oncology Tumor Board during the Friday Satellite Symposium preceding the ASH Annual Meeting. In addition, Dr. Goy will moderate an oral and poster session featuring lymphoma chemotherapy.

"We are proud to contribute such a significant body of scientific research," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. "We are thankful to the patients who entrust us and participate in our clinical trials, the physicians who lead this research at our institution, and the institutions we collaborate with to help us accelerate the development of novel and combination therapies."

For those attending the ASH annual meeting, visit the John Theurer Cancer Center at Booth 1923. The following are abstracts and presentations at ASH annual meeting from the John Theurer Cancer Center. For ongoing updates, please visit jtcancercenter.org/ash2011.

John Theurer Cancer Center 2011 ASH Abstract Highlights:

Lymphoma

  • 269 - Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study, Andre Goy, MD, et al.. Oral Session: Dec. 12, 2011 Time: 8:00AM
  • 442 - The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial, Andre Goy, MD, et al.. Oral Session: Dec. 12, 2011 Time: 11:15AM
  • 557 - High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma, Andre Goy, MD, et al.. Oral Session: Dec. 12, 2011 Time: 3:45PM
  • 585 - High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma, K. Stephen Suh, PhD, Andre Goy, MD, et al.. Oral Session: Dec. 12, 2011 Time: 3:15PM
  • 882 - Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL), Tatyana Feldman, MD, Andre Goy, MD, et al.. Oral Session: Dec. 12, 2011 Time: 7:30PM
  • 2718 - Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy, Andre Goy, MD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM
  • 3086 - A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplants, Anthony R. Mato, MD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Tatyana Feldman, MD, David H. Vesole, MD, PhD, Tania Zielonka, Theresa Amatucci, Alexandria Campaiola, BSN, Arun K. Singavi, BS, Clement Cousin, MBBS and Andre Goy, MD, Poster Session: Dec. 11, 2011 Time: 6:00PM-8:00PM

Multiple Myeloma

  • 480 - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial, David S. Siegel, MD, PhD, et al.. Dec. 12, 2011 Time: 11:45AM
  • 631 - Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM), David H. Vesole, MD, PhD, et al.. Oral Session: Dec. 12, 2011 Time: 2:45PM
  • 634 - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results, David S. Siegel, MD, PhD, et al.. Oral Session: Dec. 12, 2011 Time: 3:30PM
  • 653 - Myeloma - Therapy, excluding Transplantation: Novel drugs in relapsed/refractory myeloma patients, David S. Siegel, MD PhD, Dec. 12, 2011 Time: 4:30-6:00 PM
  • 811 - Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial, David H. Vesole, MD, PhD, et al.. Oral Session: Dec. 12, 2011 Time: 5:00PM
  • 813 - Final Results From the Bortezomib-nave Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM, David H. Vesole, MD, PhD, et al... Oral Session: Dec. 12, 2011 Time: 5:00PM
  • 1024 - The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development, David S. Siegel, MD, PhD, et al.. Oral Session: Dec. 13, 2011 Time: 8:15AM
  • 1875 - Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study, David S. Siegel, MD, PhD, et al.. Poster Session: Dec. 10, 2011 Time: 5:30PM- 7:30PM 8:00PM
  • 1877 - Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib, David S. Siegel, MD, PhD, et al.. Poster Session: Dec. 10, 2011 Time: 5:30PM 7:30PM
  • 2877 - Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays Comparison with Electrophoretic Responses in Multiple Myeloma (MM), David H. Vesole, MD, PhD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM
  • 2930 - A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM
  • 3969 - The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials, David S. Siegel, MD, PhD, et al.. Poster Session: Dec. 12, 2011 Time: 6:00PM 8:00PM
  • 3986 - Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma, Joshua R. Richter, MD, Elizabeth Bilotti, MSN, RN, Laura McBride, Linda Schmidt, Palka Anand, Ann McNeill, Urszula Bednarz, David H. Vesole, MD, PhD and David S. Siegel, MD, PhD, Poster Session: Dec 12, 2011 Time: 6:00PM 8:00PM
  • 3989 - Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, David S. Siegel, MD, PhD, et al.. Poster Session: Dec. 12, 2011 Time: 6:00PM-8:00PM
  • 4162 - Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma, Michele L. Donato, MD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD , Barbara Adler-Brecher, Eiswarya Chichili, MD, Andrew L. Pecora, MD, Phyllis McKiernan, APN, Melissa Baker, APN, Themba Nyirenda, PhD, Elizabeth Bilotti, MSN, RN, Andre Goy, MD and Scott D. Rowley, MD, Poster Session: Dec. 12, 2011 Time: 6:00PM-8:00PM
  • Friday Satellite Symposium: International Hematologic Oncology Tumor Board: Practical Perspectives on Current Challenging Cases of Multiple Myeloma, David S. Siegel, MD, PhD, et al.. Dec. 9, 2011 Time: 6:30PM 9:00PM

Leukemia

  • 254 - CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in ≤65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report, Stuart L. Goldberg, MD, et al.. Oral Session: Dec. 12, 2011 Time: 7:15AM
  • 2619 - Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients, Stuart L. Goldberg, MD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM
  • 2859 - Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study), Stuart L. Goldberg, MD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM
  • 3768 - Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd, Stuart L. Goldberg, MD, et al.. Poster Session: Dec. 12, 2011, Time: 6:00PM 8:00PM

Blood and Marrow Stem Cell Transplantation

  • 1 - Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial, Scott D. Rowley, MD, et al.. Oral Session: Dec. 11, 2011 Time: 2:05PM
  • 504 - Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR), David H. Vesole, MD, PhD, et al.. Oral Session: Dec. 12, 2011 Time: 11:45AM
  • 824 - Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT), David H. Vesole, MD, PhD, et al.. Oral Session: Dec. 12, 2011 Time: 4:45PM
  • 3086 - A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplants Performed At John Theurer Cancer Center, Anthony R Mato, MD, Andrew L Pecora, MD, Scott D Rowley, MD, Michele L Donato, MD, Stuart L. Goldberg, MD, Tatyana Feldman, MD, David H. Vesole, MD, PhD, Tania Zielonka, Theresa Amatucci, Alexandria Campaiola, BSN, Arun K Singavi, BS, Clement Cousin, MBBS and Andre Goy, MD, Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM

Hematological Malignancies

  • 2477 - Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237) An Investigational Aurora A Kinase Inhibitor in Patients with Advanced Hematologic Malignancies, Andr Goy, MD, et al.. Poster Session: Dec. 11, 2011 Time: 6:00PM 8:00PM


'/>"/>

Contact: Amy Leahing
amy.leahing@zibbel.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Related biology news :

1. Registration for the XIX International AIDS Conference (AIDS 2012) opens Dec. 1
2. Arizona Engineering associate professor earns national recognition
3. Iowa State engineers establish national panel to advance a carbon negative economy
4. International team to drill beneath massive Antarctic ice shelf
5. Story tips from the US Department of Energys Oak Ridge National Laboratory, November 2011
6. Marine Biological Laboratory Course Director Eric Davidson awarded International Prize for Biology
7. Veritec and National Identity Solutions (NIS) Sign Significant License Agreement Entering Into a $500 Billion Marketplace
8. Journal of the Chinese Chemical Society expands international reach with Wiley-VCH
9. International symposium explores genetic link to mesothelioma and other cancers
10. Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification
11. NOAA releases status on Florida Keys National Marine Sanctuary marine resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... ... ... Anton Paar USA, located in Ashland, Virginia is pleased to announce that construction ... a third office building to the current facilities. , Growth is nothing new. ... with office space adjacent to the previous main building. Through remodels and new construction, ...
(Date:5/19/2016)... 2016 - I dati saranno ... il 52 ° Congresso della ... - Le conclusioni dello studio indicano un tasso ... di cui il 90% presenta una d urata della ... Il settantadue per cento dei pazienti ha riscontrato un beneficio ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more than ... asthma complications.* Costing more than $56 billion in direct costs annually, asthma remains ... too many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and ...
(Date:5/17/2016)... Saudi Arabia (PRWEB) , ... May 17, 2016 ... ... the biopharmaceutical industry, and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have ... of diagnostic services to healthcare providers in the Kingdom of Saudi Arabia (KSA). ...
Breaking Biology Technology: